Bio Medica Laboratories IPO GMP Day 1 21 May 2026: Indore Parenteral Injectable Manufacturer Opens on NSE SME With Nil Grey Market Premium

The Bio Medica Laboratories IPO opened for subscription today, 21 May 2026 (Day 1), on the NSE SME platform. The Rs 52.43 crore issue, comprising a fresh issue of 33,95,000 shares and an offer for sale (OFS) of 3,77,000 shares, is priced at Rs 132 to Rs 139 per share. The grey market premium stands at Rs 0 as of 21 May per IPOGuru, indicating no listing gain expectation from the grey market at this stage. Day 1 subscription data is at 0x in opening hours, which is standard for the first session of any NSE SME issue. The Bio Medica Laboratories IPO closes on 25 May 2026 and lists on NSE SME on 29 May 2026.

Bio Medica Laboratories IPO Day 1 Key Data

• Day 1 Date: 21 May 2026 (Today)
• Close Date: 25 May 2026
• Allotment Date: 26 May 2026
• Share Credit: 27 May 2026
• Listing Date: 29 May 2026 on NSE SME
• Price Band: Rs 132 to Rs 139 per share
• Issue Size: Rs 52.43 crore (Fresh 33,95,000 shares + OFS 3,77,000 shares = 37,72,000 total)
• Face Value: Rs 10 per share
• Lot Size: 1,000 shares per lot
• Minimum Retail Application: 2 lots (2,000 shares) at Rs 139 upper band = Rs 2,78,000
• Category Split: QIB 50%, NII 15%, Retail 35%
• Day 1 Subscription (Opening Hours): 0x (data building through the session)
• GMP Day 1: Rs 0 (nil per IPOGuru and IPOWatch)
• Lead Manager: Skyline Financial Services Pvt Ltd (Registrar)

Track Bio Medica Laboratories IPO subscription live on the Check the Univest Screener for live data.

About Bio Medica Laboratories: Parenteral Pharmaceutical CDMO

Bio Medica Laboratories Limited was incorporated in August 2015 in Indore, Madhya Pradesh, and operates as a pharmaceutical contract development and manufacturing organisation (CDMO) specialising in parenteral formulations. The company manufactures liquid injectables (LVP and SVP) and dry powder injectables for both human healthcare and veterinary segments, operating on a B2B contract manufacturing model where it supplies finished pharmaceutical products to branded pharma companies across India.

The manufacturing facility is GMP-certified by the Madhya Pradesh Food and Drug Administration and GLP-certified, ensuring compliance with the quality standards required by pharma clients. The company has expanded its geographic reach to over 11 Indian states including Madhya Pradesh, Gujarat, Karnataka, Tamil Nadu, Rajasthan, Maharashtra, Uttar Pradesh and others. The client base includes pharmaceutical companies that outsource manufacturing of ethical drugs, generic medicines and OTC products to Bio Medica Laboratories under white-label arrangements.

• Business Model: B2B contract manufacturing of parenteral formulations (no own brand)
• Products: Liquid injectables (LVP/SVP), dry powder injectables, ethical drugs, OTC pharma, veterinary injectables
• Certifications: GMP (MP FDA) + GLP certified
• Presence: 11+ Indian states
• Incorporated: August 2015, Indore, Madhya Pradesh

Tap to Access Best Research Pieces on Univest

Use of IPO Proceeds

• Debt Repayment: Rs 6.50 crore — repayment or prepayment of borrowings from banks and financial institutions
• New Manufacturing Facility Capex: Rs 28.50 crore — construction and equipment for a new manufacturing unit at the existing Indore premises, expanding parenteral production capacity
• General Corporate Purposes: Balance of fresh issue proceeds
• OFS Proceeds: Rs 5.24 crore from OFS goes to existing selling shareholders — does not flow to the company

The Rs 28.50 crore capex for the new manufacturing unit is the most significant use of proceeds. Expanding parenteral capacity directly enables the company to scale CDMO contracts, as pharmaceutical clients look for partners who can absorb larger batch orders. The Indore location gives Bio Medica Laboratories proximity to Madhya Pradesh’s growing pharmaceutical cluster and access to skilled pharmaceutical manufacturing talent.

Why the GMP Is Zero on Day 1

A nil GMP for the Bio Medica Laboratories IPO on Day 1 does not signal a negative outcome — it reflects the absence of speculative positioning in a small-to-mid-sized Rs 52.43 crore NSE SME issue. Grey market premiums for pharmaceutical CDMO companies typically emerge on Day 2 or Day 3 as subscription data builds. For context, multiple successful NSE SME pharma listings in recent months have started with zero or marginal GMP on Day 1 before building momentum as QIB and NII subscriptions become visible.

The QIB category holds 50 percent of the Bio Medica Laboratories IPO allocation. QIBs almost universally wait until Day 2 or Day 3 before committing, which means the 0x Day 1 subscription in opening hours is entirely standard. The more meaningful signal will come from Day 2 and Day 3 subscription data and any GMP movement that accompanies institutional activity. Monitor the Day 1 close subscription data at 6 PM on NSE for the first real demand signal.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces on Bio Medica Laboratories IPO live Day 1 subscription and GMP on Univest!

Risks and Considerations

• OFS Component: 3.77 lakh shares (approximately 10% of the issue) are being sold by existing shareholders. Investors should assess why promoters are partially exiting at this stage.
• Nil GMP: No listing gain expectation means this is a pure fundamental application. Only apply if you have conviction in the parenteral CDMO growth story and are comfortable with small-cap NSE SME risk.
• High Minimum Investment: Rs 2,78,000 for 2,000 shares (2 lots at Rs 139 upper band) is among the higher minimums for this week’s SME IPOs.
• B2B Dependency: As a pure CDMO with no own brand, Bio Medica Laboratories is dependent on its pharmaceutical company clients for orders. Loss of any major client impacts revenue significantly.
• Regulatory Risk: Pharmaceutical manufacturing is subject to GMP compliance inspections. Any regulatory action from FDA authorities could halt manufacturing and impact revenue.

Conclusion

The Bio Medica Laboratories IPO opened on Day 1 today (21 May 2026) on NSE SME with a nil GMP and 0x opening hours subscription. The Rs 52.43 crore issue prices between Rs 132 and Rs 139. The Indore-based parenteral CDMO with GMP and GLP certifications and 11-plus state presence offers a fundamental play on India’s pharmaceutical outsourcing growth. The Rs 28.50 crore capex for capacity expansion is the key growth catalyst from the IPO proceeds. Track live subscription data on Univest and monitor Day 2 data closely for QIB demand signals. The issue closes 25 May and lists 29 May on NSE SME. Consult a SEBI-registered advisor before investing.

FAQs on Bio Medica Laboratories IPO Day 1

What is the Bio Medica Laboratories IPO GMP on Day 1?

Ans. The Bio Medica Laboratories IPO GMP is Rs 0 (nil) on Day 1 (21 May 2026) per IPOGuru and IPOWatch. No grey market premium has been established. GMP may build from Day 2 onwards as subscription data and QIB demand become visible. This is a fundamental application, not a listing-gain trade.

What is the Bio Medica Laboratories IPO minimum investment?

Ans. The minimum retail application is 2 lots of 1,000 shares each (2,000 shares) at the upper band of Rs 139, requiring Rs 2,78,000. The issue closes 25 May and lists on NSE SME on 29 May 2026. Allotment is on 26 May.

What does Bio Medica Laboratories manufacture?

Ans. Bio Medica Laboratories manufactures parenteral pharmaceutical formulations including liquid injectables (LVP and SVP) and dry powder injectables for both human healthcare and veterinary segments on a B2B contract manufacturing basis. The company is GMP and GLP certified and serves 11+ Indian states.